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Small-molecule tankyrase 1 and tankyrase 2 (TNKS1/2) inhibitors are effective anti-
tumor agents in selected tumor cell lines and mouse models. Here, we character-
ized the response signatures and the in-depth mechanisms for the antiproliferative
effect of tankyrase inhibition (TNKSi). The TNKS1/2-specific inhibitor G007-LK was
used to screen 537 human tumor cell lines and a panel of particularly TNKSi-sensi-
tive tumor cell lineswas identified. Transcriptome, proteome, andbioinformatic an-
alyses revealed the overall TNKSi-induced response signatures in the selected
panel. TNKSi-mediated inhibition of wingless-type mammary tumor virus integra-
tion site/b-catenin, yes-associated protein 1 (YAP), and phosphatidylinositol-4,5-bi-
sphosphate 3-kinase/AKT signaling was validated and correlated with lost expres-
sion of the key oncogene MYC and impaired cell growth. Moreover, we show that
TNKSi induces accumulation of TNKS1/2-containing b-catenin degradasomes func-
tioning as core complexes interacting with YAP and angiomotin proteins during
attenuation of YAP signaling. These findings provide a contextual and mechanistic
framework for using TNKSi in anticancer treatment that warrants further compre-
hensive preclinical and clinical evaluations.
INTRODUCTION
Anticancer treatment, using small-molecule tankyrase 1 and tankyrase 2 (TNKS1/2) inhibitors, shows in vivo ef-
ficacy against colorectal cancer (Lau et al., 2013; Waaler et al., 2012) and osteosarcoma (Martins-Neves et al.,
2018) in mouse xenograft models. The therapeutic effect can be enhanced and broadened by combining tank-
yrase inhibition (TNKSi) with inhibitors of phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K), epidermal
growth factor receptor, ormitogen-activated protein kinase against colorectal cancer xenografts (Schoumacher
et al., 2014; Solberg et al., 2018). Recently, combining TNKSi with antibody-based inhibition of programmed cell
death 1 has shown effect in syngeneic melanoma mouse models (Waaler et al., 2020b).
TNKS1/2 are members of the poly (ADP-ribose) polymerase (PARP) family of enzymes that control protein
turnover and activities by catalyzing the post-translational modification poly-ADP-ribosylation (Haikarainen
et al., 2014; Smith et al., 1998). The poly-ADP-ribose signal is subsequently recognized by the E3 ubiquitin
ligase ring finger protein 146 leading to polyubiquitination of the target protein and subsequent protea-
somal degradation (Callow et al., 2011; Haikarainen et al., 2014; Nie et al., 2020; Zhang et al., 2011). Inde-
pendent of the catalytic activity, TNKS1/2 also provide structure-based scaffolding functions (Mariotti et al.,
2016; Pollock et al., 2019; Seimiya and Smith, 2002).
Multiple potent small-molecules have been developed to target the catalytic site of TNKS1/2 (Bregman et al.,
2013; Huang et al., 2009; Johannes et al., 2015; Mizutani et al., 2018; Shultz et al., 2013; Voronkov et al., 2013;
Waaler et al., 2020a). Among these, the triazole-based series including JW74 (Waaler et al., 2011), G007-LK (Vor-
onkov et al., 2013), OD336 (compound 16) (Anumala et al., 2017), and OM-1700 (compound 13) (Waaler et al.,
2020a) target the adenosine binding pocket of the TNKS1/2 catalytic domain with high selectivity, whereby
G007-LK shows a favorable pharmacokinetic profile in mice (Voronkov et al., 2013). In contrast, agents like
XAV939, that bind to the nicotinamide binding pocket of the catalytic domain, are less selective in that they
also inhibit additional PARP family members (Haikarainen et al., 2014; Huang et al., 2009).iScience 24, 102807, July 23, 2021 ª 2021 The Authors.





ArticleDespite the progress in structural development, no TNKS1/2 inhibitor has yet entered clinical use for any
application (Ferri et al., 2017). Clinical tankyrase inhibitor development has so far been hampered by con-
cerns over intestinal toxicity and other on-target or signaling-pathway-specific side effects (Fujita et al.,
2018; Lau et al., 2013; Zhong et al., 2016a, 2016b). Although current preclinical stage tankyrase-specific in-
hibitors, includingG007-LK, do not display the chemical properties required for approval for human testing
(Voronkov et al., 2013), research to develop additional TNKS1/2 inhibitors for clinical use is actively pursued
(Ferri et al., 2017; Waaler et al., 2020a).
TNKS1/2 can orchestrate the activities of several biological mechanisms including proliferation, differenti-
ation, energy metabolism, vesicle transport, telomere homeostasis, and mitotic spindle formation through
a multitude of direct poly-ADP-ribosylation targets (Haikarainen et al., 2014; Kim, 2018; Wang et al., 2020;
Zimmerlin and Zambidis, 2020). Importantly, TNKSi has been reported to inhibit key cancer-promoting
signaling pathways (Sanchez-Vega et al., 2018), such as the wingless-typemammary tumor virus integration
site (WNT)/b-catenin pathway (Huang et al., 2009), the yes-associated protein 1 (YAP) pathway (Wang et al.,
2015), the PI3K/AKT serine/threonine kinase 1 (AKT) pathway (Li et al., 2015), and the notch receptor
(NOTCH) pathway (Bhardwaj et al., 2017). In addition, TNKSi-induced AMP-activated protein kinase
(AMPK) activation, followed by suppression of tumorigenesis, has been described (Li et al., 2019).
In WNT/b-catenin signaling, AXIN1 and AXIN2 proteins control the formation of the b-catenin destruction
complex, also termed as b-catenin degradasome, which also contains adenomatous polyposis coli (APC)
and glycogen synthase kinase 3 beta (GSK3b) (Lee et al., 2003; Thorvaldsen et al., 2015). TNKS1/2
poly(ADP-ribosyl)ate AXIN1 and AXIN2 proteins leading to their degradation and subsequent activation
of WNT/b-catenin signaling (Huang et al., 2009). Hence, TNKSi results in stabilization of AXIN proteins,
b-catenin degradasome accumulation and blockade of WNT/b-catenin signaling (Huang et al., 2009; Thor-
valdsen et al., 2015). In the Hippo signaling pathway, TNKS1/2 similarly poly-ADP-ribosylate and induce
degradation of angiomotin (AMOT), angiomotin-like 1 (AMOTL1), and angiomotin-like 2 (AMOTL2) pro-
teins (Wang et al., 2015). Consequently, TNKSi stabilizes AMOT proteins that in turn change the subcellular
location of the transcription cofactors YAP and WW domain containing transcription regulator 1 (WWTR1,
also known as TAZ), resulting in decreased YAP signaling activity (Troilo et al., 2016; Wang et al., 2015).
Notably, WNT/b-catenin and YAP signaling may interface in the b-catenin degradasome: In WNT/b-cate-
nin signaling-inactive cells, YAP and TAZ can accumulate in the b-catenin degradasome, while in WNT/b-
catenin signaling-active cells, YAP and TAZ can dislocate from the b-catenin degradasome leading to their
nuclear accumulation and YAP signaling activation (Azzolin et al., 2014). In the PI3K/AKT signaling pathway,
TNKS1/2 were reported to target and induce turnover of phosphatase and tensin homolog (PTEN), a phos-
phatase that opposes PI3K/AKT signaling antagonist (Li et al., 2015). As a consequence, AKT could be in-
activated by TNKSi-mediated stabilization of PTEN (Li et al., 2015).
The master transcriptional regulator MYC proto-oncogene (MYC) is deregulated in >50% of human can-
cers, in line with a central function in controlling a multitude of oncogenic processes including differenti-
ation, proliferation, and apoptosis (Chen et al., 2018). WNT/b-catenin, YAP, and PI3K/AKT signaling
pathways are all promoters of MYC transcription in cancer cells (He et al., 1998; Huh et al., 2019; Kress
et al., 2015; Neto-Silva et al., 2010).
The vast majority of studies on the antitumor effect of TNKSi focus on the impact on individual signaling path-
ways rather than examining the overall downstream biological effects of TNKSi. Here, we used the TNKS1/2-se-
lective inhibitor G007-LK to screen 537 tumor cell lines for an antiproliferative effect and identified a subset
highly TNKSi-sensitive cell lines originating from the colon, kidney, ovary, and lung. In this subset, functional
andmolecular analyses revealed that TNKSi can context-dependently antagonize the oncogenic signalingpath-




Proliferation screen identifies human tumor cell lines susceptible to growth inhibition by the
selective tankyrase inhibitor G007-LK
Previous reports have shown that TNKSi can block proliferation and reduce viability in a limited subset of
cancer cell lines in vitro (Kim, 2018; Nusse and Clevers, 2017). However, little is known regarding the anti-
proliferative effect of TNKSi against a vast number of cancer types, let alone the subsets within each cancer
type. To evaluate TNKSi-mediated inhibition of cell growth, the TNKS1/2-specific inhibitor G007-LK was2 iScience 24, 102807, July 23, 2021
Figure 1. Proliferation screen identifies human tumor cell lines susceptible to growth inhibition by the selective
tankyrase inhibitor G007-LK.
(A) Proliferation/viability screen: NCI-60 and Genentech tumor cell line panels were treated with G007-LK for 48 and 72 hr
respectively. The number (table) and percentage (graph) of GI 25 value hits (25% cell growth inhibition at a concentration
<1 mM G007-LK) versus the total number of tumor cell lines established from various tissues (only tissues represented by
R 14 cell lines are shown).
(B) Tumor cell lines were selected for further analysis (GI 50 values [50% cell growth inhibition] at < 200 nM G007-LK, light
blue) including COLO 320DM cells (Lau et al., 2013) and in comparison with RKO control cells (blue).
(C) Re-screening using endpoint MTS proliferation assay (Abs492) for the indicated concentrations of G007-LK for 4–8 days
relative to control (100%, 0.01% DMSO) and experiment time 0 values (t0, set to 0%). One-way ANOVA tests (Holm-Sidak
method versus control) are indicated by *** (p < 0.001) and one-way ANOVA on ranks tests (Dunn’s method versus
control) are indicated by y (p < 0.05). Mean valuesGSD for one representative experiment of at least two repeated assays,
each with six replicates, are shown.
(D) Endpoint MTS proliferation assay GI 50-values.
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(E) Relative colony numbers (%) upon 7–11 days of treatment with G007-LK (1 mM) compared to DMSO (0.01%). Mean
values GSD for combined data from a minimum of three independent experiments with three replicates each are shown.
For E–G, I, and K, two-tailed t-tests are indicated by *** (p < 0.001), ** (p < 0.01), and * (p < 0.05) while Mann-Whitney rank-
sum tests are indicated by z (p < 0.01) and y (p < 0.05).
(F) Cell cycle alteration relative to control (%). G = gap1 phase, S = synthesis phase, G2/M = gap2/mitosis phase. Mean
values from combined data consisting of a minimum of four independent experiments are shown. For F andG, upon 72-h
treatment with G007-LK (1 mM) compared control (set to 0%, 0.01% DMSO).
(G) Induction of apoptosis relative to control. Mean values from combined data consisting of a minimum of three
independent experiments are shown.
(H) RNA sequencing analysis of the cell cycle-controlling genes MYC and CCND1 (log2, n = 2).
For H–J, after 24 h of treatment with G007-LK (1 mM) or controls (0.01% DMSO).
(I) Real-time RT-qPCR analyses of MYC and CCND1. Mean values GSD for combined data from minimum two
independent experiments and measurements with three replicates each are shown.
(J) Immunoblots of nuclear MYC and CCND1 using lamin B1 documenting protein loading, while # indicates that the same
lamin B1 immunoblot is used as loading control for both MYC and CCND1. Representative data from two or more
independent experiments are shown.
(K) Endpoint MTS proliferation assay, (Abs492) relative to control (100%) and experiment time 0 values (t0, set to 0%), 5 days
after transfection with siRNA againstMYC and EGFP (control). Mean values GSD for one experiment representative of a
minimum of two independent assays are shown.




Articlescreened against a panel of 537 human tumor cell lines, including the NCI-60 tumor cell line panel. These
human tumor cell lines originated from 29 different tissues bearing various primary diagnoses. The concen-
trations of G007-LK treatment that inhibited cell growth by 25% or 50% (GI25 and GI50 values) were deter-
mined. Out of the 537 tested tumor cell lines, 87 (16%) displayed GI 25 values < 1 mM G007-LK. These
included >20% of the cancer cell lines originating from the kidney, ovary, stomach, liver, pancreas and
lung (Figure 1A and Table S1). The screening results suggest that TNKSi obstructed the growth of a broad
range of cancer types in vitro.
The proliferation screen identified three cell lines that were particularly susceptible to the growth-inhibitory
effect of G007-LK (TNKSi-sensitive) with GI 50 values < 200 nM. These three cell lines, UO-31 (renal cancer),
OVCAR-4 (ovarian cancer), and ABC-1 (non-small-cell lung cancer), along with the previously identified
benchmark TNKSi-sensitive cell line COLO 320DM (Lau et al., 2013) (colon cancer), were submitted to sub-
sequent analyses to identify themechanisms that render themparticularly sensitive to TNKSi (Figure 1B and
Table S1). The TNKSi-insensitive colon cancer cell line RKO was included as a negative control (Mizutani
et al., 2018; Solberg et al., 2018; Tanaka et al., 2017). To verify the screening data, the panel was subse-
quently rescreened. In the retested cell lines, G007-LK significantly decreased cell growth, as measured
by colorimetric MTS viability (GI50 values: 54–844 nM) and colony assays (42–66% reduction), in all
TNKSi-sensitive cell lines, while control RKO cells remained unaffected by the treatment (Figures 1C,
1D, 1E, and S1A).
Next, cell cycle and apoptosis analyses were performed to further investigate TNKSi-induced cell growth
inhibition. In the panel of TNKSi-sensitive cell lines, only ABC-1 cells exhibited significant G1 cell cycle
arrest and apoptosis upon G007-LK treatment (Figures 1F, 1G, S1B, and S1C). By contrast, RNA
sequencing and real-time qRT-PCR analyses revealed significantly reduced transcripts of the key cell-cy-
cle-promoting genes MYC and cyclin D1 (CCND1), as well as MYC and cyclin D1 protein in all selected
TNKSi-sensitive cell lines after G007-LK treatment, but not in RKO control cells, suggesting that TNKSi is
unable to block MYC expression in RKO cells (Figures 1H–1J and S1D). Finally, to examine whether
decreased MYC expression can impair cell growth, the selected cell panel was transfected with siRNA
against MYC. Knockdown of MYC, to recapitulate the G007-LK-mediated reduction of MYC protein, re-
sulted in a significant inhibition of cell growth in all cell lines, also in RKO control cells (Figure 5K and
S1E). The results indicate that all tested cell lines depend on expression of MYC for sustained cell
proliferation.
In conclusion, the results suggest that TNKSi decreases MYC and cyclin D1 expression leading to induction
of cytotoxic G1 cell cycle arrest and apoptosis in ABC-1 cells, while overall slower cell cycle progression is
the primary cause of the cytostatic cell growth inhibition observed in COLO 320DM, UO-31, and OVCAR-4




ArticleGene expression analysis reveals that TNKSi attenuates MYC and WNT/b-catenin, YAP, and
PI3K/AKT signaling pathways
The effect of TNKSi against tumor cell proliferation may depend on the tumor type, mutation load, the
context in which the tumor cells are grown, and the intrinsic activities of various cellular pathways. To
map changes in gene expression, proteome, and cell signaling pathways and to correlate them with onco-
genic mutations, the selected cell line panel was exposed to G007-LK treatment followed by RNA
sequencing, bioinformatic analyses, and proteomics analyses.
First, a mutation analysis of the RNA sequencing data set was performed by matching mutations identified
in the selected cell lines against a set of previously defined driver oncogenes (Bailey et al., 2018). However,
apart from the relative abundant mutations in TNKSi-insensitive RKO cells, no telltale mutational patterns
unifying the 5 cell lines were identified (Table S2). Moreover, when comparing the RNA sequencing data, a
principal component analysis revealed highly different pretreatment and post-treatment transcriptional
profiles (Figure 2A).
Next, to categorize TNKSi-induced transcriptional signatures, a bioinformatics analysis identified 369–1547
statistically significant differently expressed genes (DEGs) in TNKSi-sensitive cells, while only 29 DEGs were
found in RKO control cells (Figures 2B and S2A and Table S3). Again, no robust clustering of the DEG pro-
files leading to a clear subclassification of the cell lines was observed (Figures 2C).
An Ingenuity Pathway core Analysis (IPA) was therefore applied, based on theDEG transcript profiles uncovered
by RNA sequencing, to identify statistically significant key upstream transcriptional regulating proteins. In all
four selected TNKSi-sensitive cell lines, estrogen receptor 1 (ESR1) and MYC were predicted to be downregu-
lated upstream regulators by TNKSi (Figures 2D [see top row], S2B and Table S3). For three out of the four
TNKSi-sensitive cell lines, activities of four proteins were predicted to be upregulated upstream regulators after
G007-LK treatment: Tumor protein p53 (TP53), nuclear protein 1, transcriptional regulator (NUPR1), tumor pro-
tein p73 (TP73), and BRCA1 DNA repair associated. Three proteins were predicted to be downregulated up-
stream regulators: MYC-associated factor X (MAX), YAP1, and Sp1 transcription factor (SP1) (Figures 2D and
S2B and Table S3). Several of these identified upstream regulator proteins are known to control apoptosis
and cell cycle, such as TP53 (Hafner et al., 2019), TP73 (Rodriguez et al., 2018), andMYC (Chen et al., 2018), while
MAX is associated with MYC in the MYC-MAX complex (Cascon and Robledo, 2012).
Transcription ofMYC can be regulated by several signaling pathways that contain tankyrase target proteins
including WNT/b-catenin, YAP, and PI3K/AKT signaling (He et al., 1998; Huh et al., 2019; Kress et al., 2015;
Neto-Silva et al., 2010). Within these pathways, CTNNB1 (b-catenin) was predicted to be a downregulated
upstream regulator in COLO 320DM and OVCAR-4 cells upon G007-LK treatment (Figures 2D, 2E, and S2B
and Table S3). Several of the upstream regulator proteins, predicted in the IPA core analysis, are associated
with WNT/b-catenin signaling activity: SP1 is regulated by the b-catenin destruction complex (Mir et al.,
2018), ESR1 is involved in cross talk with WNT/b-catenin signaling, while forkhead box O3 (FOXO3) can
bind and interact with b-catenin (Kouzmenko et al., 2004; Valenta et al., 2012). YAP1 was predicted to be
a downregulated upstream regulator in UO-31, OVCAR-4, and ABC-1 cells after exposure to G007-LK (Fig-
ures 2D and S2B and Table S3), while NUPR1 transcription is controlled by YAP signaling (Jia et al., 2016).
FOXO3, a central effector of PI3K/AKT signaling (Stefanetti et al., 2018), was predicted to be an upregu-
lated upstream regulator in UO-31 and ABC-1 cells (Figures 2D, 2E, and S2B and Table S3). In a previous
report, decreased NOTCH signaling was observed in a proteome analysis of TNKS1/2 knockout HEK293
cells (Bhardwaj et al., 2017). However, predictions of NOTCH1 activity were outside the threshold level
used in the IPA core analysis for all cell lines (Table S3), and no distinct downregulation of NOTCH signaling
target genes was observed in any of the cell lines (Figure S2C).
Finally, an SILAC-based proteome analysis identified 590–847 statistically significant differently expressed
proteins in the selected TNKSi-sensitive cells, while 501 proteins were found in RKO cells (Figure S2D and
Table S4). No robust clustering classifying the cell line’s protein expression profiles was observed (Fig-
ure S2E). However, among upregulated proteins, the energy metabolism-regulating proteins transketo-
lase, NADH:ubiquinone oxidoreductase subunit A8, and hydroxyacyl-CoA dehydrogenase trifunctional
multienzyme complex subunit beta were identified in aminimumof four of the cell lines after G007-LK treat-
ment (Table S4). Previous reports have shown TNKSi-mediated regulation of energy metabolism in mouse
models (Wang et al., 2020; Zhong et al., 2016a, 2016b).iScience 24, 102807, July 23, 2021 5
Figure 2. Gene expression analysis reveals that TNKSi attenuates MYC and WNT/b-catenin, YAP and PI3K/AKT
signaling pathways
(A) Principal component (PC) analysis plot showing gene expression diversity. For A–C, mRNA sequencing data for
selected human tumor cell line panel treated for 24 h with G007-LK (1 mM, n = 2) compared to control (0.01%DMSO, n = 2).
(B) Volcano plots showing the effect of G007-LK treatment on gene expression. Transformed NOISeq probability values
(-log10[1-Probability]) are plotted against log2 fold change. Genes with probability values >0.8 are highlighted in red.
(C) Heatmap of log2 fold change of genes differentially expressed in one or more cell lines.
(D) Prediction of upstream signaling pathway protein regulators (IPA core analysis) based on differentially expressed
genes identified in B and categorized using Venn analysis. Threshold: Probability values >0.8, p value of overlap <13 108
and absolute activation Z score > 0.5 or < 0.5. Key signaling pathway proteins identified are highlighted in red.
(E) Prediction of predominantly downregulated signaling pathways.




ArticleIn conclusion, the analysis of transcriptional responses to G007-LK exposure indicates a repertoire of rather
diverse regulation of signaling pathways in TNKSi- sensitive tumor cell lines. Nevertheless, TNKSi predom-
inantly leads to cell type-dependent and primary inhibition of the WNT/b-catenin, YAP, and PI3K/AKT
signaling pathways and, subsequently, counteraction of MYC-driven cell cycle progression and tumor
cell growth (Figure 2E). Hence, the effect of G007-LK against these three signaling pathways was further
investigated in the selected cell line panel.6 iScience 24, 102807, July 23, 2021
Figure 3. G007-LK inhibitsWNT/b-catenin signaling in a subset of tumor cell lines that are dependent on b-catenin
for sustained cell growth
(A) Endpoint MTS proliferation assay (Abs492) relative to control (100%) and experiment time 0 values (t0, set to 0%). Mean
values GSD for one experiment representative of a minimum of two independent assays are shown. For A–C, 5–8 days
after transfection with siRNA against CTNNB1 and EGFP (control).
For A–C, E, F, and H, two-tailed t-tests as indicated by *** (p < 0.01), ** (p < 0.01) and * (p < 0.05) while Mann-Whitney
rank-sum test is indicated by y (p < 0.05).
(B) Cell cycle alteration (%) relative to control (set to 0%). Mean values from combined data consisting of aminimum of four
independent experiments are shown.
(C) Induction of apoptosis (%) relative to control (set to 0%). Mean values from combined data consisting of a minimum of
three independent experiments are shown.
(D) Immunoblots of cytoplasmic TNKS1/2, AXIN1 and AXIN2 (upper panels), and nuclear active form of b-catenin (non-
phospho[Ser33/37/Thr41]) and total b-catenin (lower panels), after 24 or 72 hr treatment with G007-LK (1 mM) compared to
ll
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controls (0.01% DMSO). Actin (cytoplasmic) and lamin B1 (nuclear) document protein loading. Representative data
from two or more independent experiments are shown.
(E) Luciferase-based reporter assay for comparing baseline WNT/b-catenin signaling activity. The cells were transiently
co-transfected with either a superTOPflash (vector with 7 X TCF promoter binding sites driving the firefly luciferase) or a
FOPflash (control vector with mutated TCF binding sites) along with Renilla luciferase (for normalization). All samples are
relative to normalized superTOPflash signal for RKO cells (= 1). Mean values GSD for combined data from 2–4
independent experiments with three replicates each are shown. Statistically significant differences between
SuperTOPflash and FOPflash activities (TOP/FOP ratio) are indicated.
(F) IC50 and IC25 values (nM) for luciferase-based WNT/b-catenin signaling reporter assay (stably transfected with
SuperTOPflash and Renilla luciferase) upon exposure to different concentrations of G007-LK for 72 h compared to control
(0.01% DMSO).
(G) WNT/b-catenin signaling target gene transcription (RNA sequencing, log2) after 24-h treatment with G007-LK (1 mM)
compared to controls (0.01% DMSO) (n = 2). NA = not available, no RNA detection.
(H) Real-time RT-qPCR analysis of AXIN2 upon 24 hr G007-LK treatment (1 mM) relative to control (0.01% DMSO). Mean
values GSD for combined data from two independent experiments with three replicates each are shown.




ArticleG007-LK inhibits WNT/b-catenin signaling in a subset of tumor cell lines that are dependent
on b-catenin for sustained cell growth
Following G007-LK exposure, b-catenin was predicted by the IPA core analysis to be a downregulated up-
stream regulator in COLO 320DM and OVCAR-4 cells, indicating reduced WNT/b-catenin signaling
(Figure 2). To evaluate if reducedWNT/b-catenin signaling controls cell growth, the cell line panel was sub-
jected to siRNA-mediated knock down of CTNNB1 to recapitulate G007-LK-mediated b-catenin reduction
(Figure S3A). Cell growth was significantly inhibited in only COLO 320DM and OVCAR-4 cells (Figures 3A
and S3B), while significant G1 cell cycle arrest and induction of apoptosis was observed only in COLO
320DM cells (Figures 3B, 3C, S3C, and S3D).
Western blot analysis was applied to the selected cell line panel to explore the effect of G007-LK treatment
on its intended targets TNKS1/2 and also WNT/b-catenin signaling. G007-LK treatment induced, as previ-
ously shown (Lau et al., 2013), either a stabilization or a destabilization of TNKS1/2 in all cell lines (Fig-
ure 3D). AXIN1 was stabilized in all cell lines, while stabilization of AXIN2 and destabilization of the inactive
and phosphorylated form of GSK3b was detected in only COLO 320DM and ABC-1 cells (Figures 3D and
S4A). b-catenin was reduced in COLO 320DM cells after 24-h exposure to G007-LK, while a moderate
reduction was seen in OVCAR-4 and ABC-1 cells after 72-h treatment (Figures 3D and S4A).
To assess endogenous WNT/b-catenin signaling pathway activities, the cell line panel was transiently
cotransfected with a vector containing WNT/b-catenin signaling-responsive promoter driving firefly
luciferase expression (superTOPflash), or control vector (FOPflash), along with Renilla luciferase for normal-
ization. COLO 320DM cells (APCmutated) demonstrated high luciferase activity compared to RKO cells
(APCwild-type), indicating high endogenous WNT/b-catenin signaling activity (Figure 3E). OVCAR-4 and
ABC-1 cells showed moderate but significant increases in superTOPflash signal when compared to the
FOPflash signal, suggesting rather low endogenous WNT/b-catenin signaling activities (Figure 3E). In sta-
ble superTOPflash and Renilla luciferase transfectants, a decrease in WNT/b-catenin signaling activity was
only seen in COLO 320DM cells exposed to various doses of G007-LK (Figures 3F and S4C). Although tran-
scription of AXIN2, a cell type-universal and negative-feedback-controlling target gene, was significantly
reduced in COLO 320DM, OVCAR-4, and ABC-1 cells, RNA sequencing analyses revealed that transcrip-
tion of a panel of WNT/b-catenin signaling target genes was reduced predominantly in COLO 320DM cells
(Figures 3E and 3G).
In APC-mutated colorectal cancer cells, TNKSi resulted in the accumulation of cytoplasmic puncta and b-
catenin degradasomes containing TNKS1/2, AXIN1/2, APC, GSK3b, and b-catenin (Thorvaldsen et al.,
2015). Hence, to gain further knowledge regarding b-catenin degradasome accumulation in the selected
cell line panel, structured illumination microscopy imaging was performed to visualize TNKS1/2 and b-cat-
enin upon G007-LK treatment. Decreased accumulation of nuclear b-catenin, and formation of distinct
cytoplasmic puncta with colocalized TNKS1/2 and b-catenin (Lau et al., 2013; Thorvaldsen et al., 2015;
Waaler et al., 2012), was only observed in APC-mutated COLO 320DM cells with high endogenous
WNT/b-catenin signaling activity and expression of AXIN2 protein (Thorvaldsen et al., 2017) (Figure 4).
In contrast, b-catenin localization, primarily found in the cell membrane, did not change in the other8 iScience 24, 102807, July 23, 2021
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Figure 4. Effect of G007-LK treatment on localization of b-catenin and TNKS1/2 in tumor cell lines
Immunofluorescence staining and representative confocal images of b-catenin (magenta) and TNKS1/2 (green) along
with nuclear DAPI staining (blue) upon vehicle control (0.01% DMSO) and G007-LK (1 mM) treatment (24 h) of the indicated




ArticleTNKSi-sensitive cell lines (Figure 4). Instead, TNKS1/2 puncta were found in proximity to the cell membrane
after treatment in UO-31, OVCAR-4, and ABC-1 cells (Figure 4). In RKO cells, TNKS1/2 accumulated in jux-
tanuclear puncta (Figure 4).
In conclusion, the results imply that only COLO 320DM and OVCAR-4 cells are dependent on WNT/b-cat-
enin signaling for sustained cell proliferation, while UO-31 and ABC-1 cells show resistance to b-catenin
knockdown. WNT/b-catenin signaling activity is robustly decreased by G007-LK treatment in COLO
320DM cells and modestly in OVCAR-4 and ABC-1 cells. TNKS1/2- and b-catenin-containing puncta are
found in the cytoplasm in APC-mutated COLO 320DM cells, but close to the cell membrane in UO-31, OV-
CAR-4, and ABC-1 cells.G007-LK inhibits YAP signaling in the selected cell line panel and all cell lines depend on YAP
for sustained proliferation
The IPA core analysis predicted YAP1 as a TNKSi-attenuated upstream regulator, suggestive for decreased
YAP signaling in UO-31, OVCAR-4, and ABC-1 cells (Figure 2). To assess whether decreased YAP signaling
can impair cell growth, the selected cell panel was transfected with siRNA against YAP. Knockdown of YAP,
to imitate G007-LK-mediated reduction of YAP signaling, resulted in a significant inhibition of cell growth in
all cell lines (Figure 5A).
To evaluate the effect of G007-LK on YAP signaling, the selected cell line panel was first examined byWest-
ern blot analysis. Treatment of each cell line with G007-LK stabilized AMOT, AMOTL1, and AMOTL2 pro-
teins in both cytoplasmic and nuclear extracts (Figures 5B and S5A), consistent with earlier reports using
HEK293T cells (Wang et al., 2015), Nuclear YAP accumulation was enhanced in UO-31, OVCAR-4, and
ABC-1 cells, similar to recent observations (Kierulf-Vieira et al., 2020; Waaler et al., 2020b), while no change
in nuclear YAP levels were observed in COLO 320DM or RKO cells. Moreover, cytoplasmic YAP was not
affected in any cell lines following TNKSi (Figure S5A). The results are in contrast with previous publications
showing lowered levels of nuclear YAP upon TNKSi (Wang et al., 2015, 2016) (Figures 5B and S5A).
Although no reduction in nuclear YAP levels was observed in the selected cell line panel subjected to
TNKSi, RNA sequencing analyses showed that transcription of a panel of YAP signaling target genes
was decreased, in all TNKSi-sensitive cell lines and to a lesser extent in RKO cells (Figure 5C). Real-time
qRT-PCR analysis showed reduced transcription of the YAP signaling target genes CCN1 (previously
named CYR61), CCN2 (previously named CTGF), and AMOTL2 in all cell lines (Figure 5D). A moderate
and significant reduction in YAP signaling luciferase reporter activity was seen in only COLO 320DM,
UO-31, and ABC-1 cells (Figure S5B).
Stabilization of AMOT proteins exposure to TNKSi (Troilo et al., 2016; Wang et al., 2015), and localization of
YAP in the degradosome (Azzolin et al., 2014), have previously been described. To obtain additional infor-
mation regarding the localization of AMOT proteins, YAP, and TNKS1/2 in the selected cell line panel,
confocal imaging was next performed.
In general, a heterogeneous distribution of nuclear and cytoplasmic YAP, and in addition, a low imaging-
detection signal for AMOTL2 in the nuclei, was observed in all cell lines regardless of G007-LK treatment
(Figures 6 and S6). However, in UO-31, OVCAR-4 and ABC-1 cells, pairwise colocalization of TNKS1/2-YAP,
TNKS1/2-AMOTL2, and AMOTL2-YAP was observed near the cell membrane only after treatment (Figures
6 and S6). In contrast, only AMOTL2-YAP colocalized in COLO 320DM cells (Figure 6). The data propose
that TNKSi-induced TNKS1/2-containing puncta can capture AMOTL2-YAP in UO-31, OVCAR-4, and
ABC-1 cells, while AMOTL2 sequesters YAP independent of TNKS1/2 in COLO 320DM cells.
In summary, the results show that all cell lines are dependent on YAP signaling for sustained cell growth.
G007-LK targets YAP signaling in all cell lines, through a mechanism involving TNKS1/2-mediated and
AMOT protein-dependent sequestering and inactivation of transcriptionally active YAP protein.10 iScience 24, 102807, July 23, 2021
Figure 5. G007-LK inhibits YAP signaling in the selected cell line panel and all cell lines depend on YAP for
sustained proliferation
(A) Endpoint MTS proliferation assay (Abs492) 5–8 days after transfection with siRNA against YAP relative to control (100%,
EGFP) and experiment time 0 values (t0, 0%). Mean values GSD for one representative experiment of minimum three
repeated assays with six replicates each are shown. ForA andD, two-tailed t-tests are indicated by ** (p < 0.01) andMann-
Whitney rank-sum tests are indicated by z (p < 0.01) and y (p < 0.05).
(B) Immunoblots of cytoplasmic AMOT, AMOTL1, and AMOTL2 (upper panels) and nuclear YAP and TAZ (lower panels)
after 24- or 72-h treatment with G007-LK (1 mM) compared to controls (0.01% DMSO). Actin and lamin B1 document
protein loading and representative data from two or more independent experiments are shown.
(C) YAP signaling target gene transcription (log2) after 24-h treatment with G007-LK (1 mM) compared to controls (0.01%
DMSO) (n = 2). NA = not available, no RNA detection.
(D) Real-time RT-qPCR analyses of YAP signaling target genes, CCN1, CCN2, and AMOTL2, upon 24-h G007-LK
treatment (1 mM) relative to control (0.01% DMSO). Mean values GSD for combined data from a minimum of two
independent experiments with three replicates each are shown.




ArticleG007-LK inhibits PI3K/AKT signaling in ABC-1 cells that depend on PI3K/AKT signaling for
sustained cell growth
The IPA core analysis predicted FOXO3 to be a TNKSi-augmented upstream regulator in UO-31 and ABC-1
cells, indicative of TNKSi-dependent decreased PI3K/AKT signaling (Figure 2). However, the RNA
sequencing analysis revealed that the transcriptional profile for activated FOXO signaling was most appar-
ently regulated in ABC-1 cells (Figure 7A). Moreover, Western blot analysis was performed to test the effect
of G007-LK treatment on PI3K/AKT signaling in the selected cell lines. Reduced presence of the activated
and phosphorylated forms of AKT, indicating blocked PI3K/AKT signaling, was only seen in ABC-1 cells
(Figures 7B and S7A).
In a previous report, TNKSi stabilized PTEN in colorectal cancer cell lines leading to downregulation of AKT
phosphorylation and its signaling activity (Li et al., 2015). In contrast, PTEN was not stabilized in any of the
cell lines after treatment, suggesting the presence of a yet-to-be-explored and PTEN-independent mech-
anism behind TNKSi-induced AKT signaling inactivation (Figure 7B). Earlier publications describe crosstalk
signaling between the PI3K/AKT and AMPK signaling pathways (Han et al., 2018; Hawley et al., 2014), and
TNKSi has been implicated in regulation of AMPK activation (Li et al., 2019). Hence, the activation status ofiScience 24, 102807, July 23, 2021 11
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Figure 6. Effect of G007-LK treatment on the localization of YAP, TNKS1/2, and AMOTL2 in tumor cell lines
Immunofluorescence staining and representative confocal images of YAP (red) and TNKS1/2 (green), YAP (red) and
AMOTL2 (green), or AMOTL2 (red) and TNKS1/2 (green), along with nuclear DAPI staining (blue) upon vehicle control
(0.01% DMSO) and G007-LK (1 mM) treatment (24 h) of the indicated cell lines. Red, antimouse antibody used. Green,




ArticleAMPK in the cell line panel upon G007-LK treatment was evaluated by Western blot analysis. In contradic-
tion with the previous report (Li et al., 2019), our analysis showed that the activated phosphorylated form of
AMPK was not upregulated in any of the cell lines by G007-LK exposure (Figure S7B). Instead, AMPK activity
was decreased in both UO-31 and ABC-1 cells after TNKSi (Figure S7B). We could therefore not explain the
TNKSi-induced AKT inactivation observed only in ABC-1 cells (Han et al., 2018; Hawley et al., 2014). To iden-
tify the precise mechanism for TNKSi-induced PI3K/AKT signaling inhibition will require further
investigation.
To evaluate if PI3K/AKT signaling is essential for continued cell growth, ABC-1 cells were treated with PI3K
and AKT inhibitors. Both inhibitors dose-dependently decreased the active and phosphorylated form of
AKT while reducing cell growth (Figure 7C). In conclusion, the data show that G007-LK can target PI3K/
AKT signaling in ABC-1 cells that are dependent on PI3K/AKT signaling for continuous cell growth.DISCUSSION
Despite more than a decade of research, much remains unclear about the molecular profiles that render
tumor cells sensitive or insensitive to the antiproliferative effect of TNKSi. Here, we describe a broad tumor
cell line screen, classifying 84% of the cell lines to be TNKSi nonresponders (GI25 values > 1 mM G007-LK)
and 16% to be TNKSi responders (GI25 values < 1 mMG007-LK) including 1.9% to be highly TNKSi-respond-
ing tumor cell lines (GI50 values < 1 mMG007-LK). >20% of the tumor cell lines originating from the kidney,
ovary, stomach, liver, pancreas, and lung were defined as TNKSi responders, suggesting that these types of
tumor cell lines are most sensitive to the antiproliferative effect of G007-LK treatment. In general, the result
indicates effectiveness of TNKSi against cell growth in subtypes of cancer across several tumor types.85–
90% of colon cancer cell lines contain mutations in APC resulting in aberrant activation of WNT/b-catenin
signaling (Fearon, 2011). Thus, colon cancer was previously regarded a particularly relevant target for
TNKSi (Lau et al., 2013). TNKSi-responsiveness in colorectal cancer has been shown to depend on the
APC mutation genotype (Schatoff et al., 2019). Yet, only two out of 41 colon cancer cell lines tested in
our screen displayed GI25 values < 1 mM G007-LK.
From the 1.9% highly TNKSi-responding tumor cell lines, a panel of heterogeneous cell lines was selected
for further analysis to identify mechanisms coupling TNKSi to attenuated proliferation. In these TNKSi-sen-
sitive cell lines, we used bioinformatics analysis of RNA sequencing data and proteome profiles to charac-
terize TNKSi effects and identified a variety of changes in response signatures. Numerous post-treatment
upstream signaling regulators were predicted to be cell-type-dependently controlled by TNKSi according
to the IPA core analysis, warranting detailed follow-up studies. While the involvement of additional
signaling pathways cannot be excluded, the overall analysis suggests that the main primary events caused
by TNKSi in the particular sensitive cell lines are a downregulation of WNT/b-catenin, YAP, and PI3K/AKT
signaling pathways followed by decreased MYC expression.
Validation experiments showed that TNKSi (i) blocked WNT/b-catenin signaling in COLO 320DM, OVCAR-4,
and ABC-1 cells; (ii) YAP signaling in all cell lines; and (iii) AKT signaling in ABC-1 cells (Figure 7D). Moreover,
TNKSi-mediated downregulation of these pathways correlated with lost expression of MYC and CCND1, sug-
gesting that downregulation of these two proteins is a shared hallmark of all tested TNKSi-sensitive cell lines (He
et al., 1998; Huh et al., 2019; Kress et al., 2015; Neto-Silva et al., 2010). In line with this notion, functional analyses
of TNKSi-mediated cell cycle arrest and apoptosis revealed the induction of a cytostatic effect in all TNKSi-sen-
sitive cell lines, with the exception of ABC-1 cells. In ABC-1 cells, TNKSi stimulatedG1 cell-cycle arrest, apoptosis
and a cytotoxic antiproliferative effect. Moreover, (i) b-catenin knockdown could recapitulate the antiprolifera-
tive effect of TNKSi treatment on COLO 320DM and OVCAR-4 cells, (ii) YAP knockdown blocked the growth of
all cell lines, whereas inhibition of (iii) PI3K/AKT signaling inhibited the proliferation of only ABC-1 cells (Fig-
ure 7D). Notably, combined TNKSi and PI3K/AKT inhibition showed additive antitumor effects in mouse colon
cancer models (Arques et al., 2016; Solberg et al., 2018). Collectively, our results suggest that TNKSi-induced
inhibition of WNT/b-catenin and YAP signaling, either individually or together, can cause a cytostatic effect,iScience 24, 102807, July 23, 2021 13
Figure 7. G007-LK inhibits PI3K/AKT signaling in ABC-1 cells that depend on PI3K/AKT signaling for sustained
cell growth
(A) FOXO-induced signaling target gene transcription (RNA sequencing, log2) after 24-h treatment with G007-LK (1 mM)
compared to controls (0.01% DMSO) (n = 2). *depicts FOXO-inactivated target genes while FOXO-activated genes are
nondepicted. NA = not available, no RNA detection.
(B) Immunoblots of cytoplasmic active AKT (phospho[Ser473] and phospho[Thr308]), total AKT and PTEN after 24- or 72-h
treatment with G007-LK (1 mM) compared to controls (0.01% DMSO) in ABC-1 cells. Actin documents protein loading.
Representative data from two or more independent experiments are shown.
(C) Left panel, endpoint MTS proliferation assay (Abs492 relative to control [100%, 0.01% DMSO] and experiment time
0 values [t0, 0%]). Right panel, representative immunoblots of cytoplasmic activate form of AKT (phospho[Ser473]) and
total AKT. Upon treatment with indicated concentrations of BKM120 (PI3K inhibitor) and API-2 (AKT inhibitor) in ABC-1
cells for 8 days (MTS analyses) or 24 h (immunoblots). One-way ANOVA tests (Holm-Sidak method versus control) are
indicated by ** (p < 0.01) and * (p < 0.05). For MTS data, mean valuesGSD for one representative experiment of minimum
two repeated assays with five replicates each are shown.
(D) Summary of TNKSi-induced reduction of signaling pathways and dependencies of signaling pathways for sustained
cell growth.




Articlewhile additional inhibition of PI3K/AKT signaling can provoke an additional cytotoxic effect. Whether similar
combinatorial effects against signaling pathways can be projected onto a larger group of tumor cell lines re-
mains to be investigated.
TNKSi stabilized AMOT, AMOTL1, and AMOTL2 in the cytoplasm and the nucleus of all cell lines. In par-
allel, YAP accumulated in nuclear extracts only in treated UO-31, OVCAR-4, and ABC-1 cells, but not
COLO 320DM and RKO cells. YAP signaling target gene expression was reduced in all cell lines. Together,
these observations are in line with recent reports that TNKSi induced accumulation of nuclear YAP corre-
lating with reduced YAP target gene expression (Kierulf-Vieira et al., 2020; Waaler et al., 2020b). However,
the observations are at odds with earlier reports that TNKSi induced a reduction of nuclear YAP leading to
reduced YAP target gene expression (Wang et al., 2015, 2016).
When performing imaging, nuclear AMOTL2 levels were close to, or below the detection threshold,




ArticleUO-31, OVCAR-4, and ABC-1 cells, puncta containing TNKS1/2-YAP, TNKS1/2-AMOTL2, and AMOTL2-
YAP were found near the cell membrane following TNKSi. The results suggest that TNKS1/2-containing
b-catenin degradasomes (Thorvaldsen et al., 2015) not only can physically interact with YAP, as previously
suggested (Azzolin et al., 2014), but also function as complexes containing AMOT proteins (Wang et al.,
2015). In contrast, the imaging of COLO 320DM cells revealed the formation of TNKSi-induced cytoplasmic
TNKS1/2-puncta that colocalized with b-catenin, indicating b-catenin degradasome accumulation (Lau
et al., 2013; Thorvaldsen et al., 2015; Waaler et al., 2012). However, in these cells, AMOTL2 and YAP colo-
calized with each other but not with TNKS1/2. Hence, similar to a previously proposed model (Wang et al.,
2015), our observations suggest that AMOT proteins sequester YAP independent of TNKS1/2-containing
b-catenin degradasomes in COLO 320DM cells. Notably, the APC-mutated cell line COLO 320DM, display-
ing a high endogenous WNT/b-catenin signaling activity, expresses higher levels of AXIN2 protein
compared to the other non-APC-mutated cell lines in the selected panel. In a previous report, loss of
expression of AXIN2, but not AXIN1, was associated with disintegration of TNKSi-induced cytoplasmic
puncta (Thorvaldsen et al., 2017). The precise mechanism for TNKSi-dependent regulation of YAP
signaling, and the association with the b-catenin degradasome, is currently under investigation.
In summary, the results provide evidence that TNKSi treatment is effective against subtypes of cancer cell
lines across several tumor types. In four identified TNKSi-sensitive cell lines, TNKSi functions by context-
dependent targeting of multiple signaling pathways including WNT/b-catenin, YAP and/or PI3K/AKT
signaling, followed by loss of MYC expression and the induction of either cytostatic or cytotoxic effects,
culminating in impaired tumor cell growth. These findings warrant further comprehensive preclinical and
clinical evaluation of TNKSi as monotherapy or combination therapy for cancer.Limitations of study
Our study identified several TNKSi-sensitive tumor cell lines, and the downstream in-depth analysis
focused on only a small subset of highly sensitive cell lines originating frommultiple tissues. These cell lines
contain highly diverse oncogenic mutations, gene and protein expression profiles as well as cell signaling
pathway activities, and as a consequence, prediction and identification of shared pretreatment and post-
treatmentmarkers was influenced. Numerous TNKSi-induced changes in activities of signaling pathways, in
addition toWNT/b-catenin, YAP, and PI3K/AKT signaling pathways, were predicted and detailed follow-up
studies are clearly needed. The experiments provide only a limited description of TNKSi-dependent regu-
lation of YAP signaling, and the results contradict with previous descriptions of TNKSi-regulated PTEN/
PI3K/AKT and AMPK signaling pathways activities, indicating that further research is needed to identify
the precise mechanisms involved.STAR+METHODS
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KEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
MYC Cell Signaling Technology Cat#5605; RRID: AB_1903938
CCND1 Abcam Cat# ab16663; RRID: AB_443423
TNKS1/2 Santa Cruz Biotechnology Cat#sc-8337; RRID: AB_661615
AXIN1 Cell Signaling Technology Cat#2087; RRID: AB_2274550
AXIN2 Cell Signaling Technology Cat#2151; RRID: AB_2062432
non-phospho (active) b-catenin Cell Signaling Technology Cat#8814; RRID: AB_11127203
phospho b-catenin (Ser33/37/Thr41) Cell Signaling Technology Cat#9561; RRID: AB_331729
b-catenin BD Biosciences Cat#610153; RRID: AB_397554
GSK3b Cell Signaling Technology Cat#12456; RRID: AB_2636978
phospho-GSK3b (Ser9) Cell Signaling Technology Cat#9323; RRID: AB_2115201
AMOT Santa Cruz Biotechnology Cat#sc-166924; RRID: AB_10609353
AMOTL1 Thermo Fisher Scientific Cat#PA5-42267; RRID: AB_2606805
AMOTL2 Thermo Fisher Scientific Cat#PA5-78770; RRID: AB_2745886
AMOTL2 Santa Cruz Biotechnology Cat#sc-398261; RRID:N/A
YAP Santa Cruz Biotechnology Cat#sc-101199; RRID: AB_1131430
TAZ Sigma Aldrich Cat#HPA007415; RRID: AB_1080602
AKT Cell Signaling Technology Cat#9272; RRID: AB_329827
phospho-AKT (Ser473) Cell Signaling Technology Cat#4060; RRID: AB_2315049
phospho-AKT (Thr308) Cell Signaling Technology Cat#9275; RRID: AB_329828
PTEN Cell Signaling Technology Cat#9552; RRID: AB_10694066
AMPKa Cell Signaling Technology Cat#2793; RRID: AB_915794
phospho-AMPKa (Thr172) Cell Signaling Technology Cat#2535; RRID: AB_331250
Actin Sigma Aldrich Cat#A2066; RRID: AB_476693
lamin B1 Abcam Cat#ab16048; RRID: AB_10107828
Bacterial and virus strains
SuperTOP-luciferase (WNT/b-catenin signaling
pathway reporter with 7xTCF binding sites:
SuperTOPflash)
Gift from Dr. Vladimir Korinek) N/A
FOPflash (negative control reporter with mutated
TCF binding sites: SuperFOPflash-luciferase)
Gift from Dr. Vladimir Korinek) N/A





Renilla luciferase (pRL-TK) Promega Cat#E2241
7TFP (7xTcf-FFluc//SV40-PuroR) Addgene, provided by Dr. Roel Nusse RRID: Addgene_24308
pMD2.G (VSV-G envelope expressing plasmid) Addgene, provided by Dr. Didier Trono RRID: Addgene_12259
psPAX2 (lentiviral packaging plasmid) Addgene, provided by Dr. Didier Trono RRID: Addgene_12260
Chemicals, peptides, and recombinant proteins
G007-LK ChemRoyal and Mercachem N/A
BKM120 Chemietek Cat#CT-BKM120
API-2 Tocris Bioscience Cat#2151
(Continued on next page)
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Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
NP40 cell lysis buffer Invitrogen Cat#FNN0021
RIPA lysis buffer Thermo Fisher Scientific Cat#89901
RPMI 1640 Medium for SILAC Thermo Fisher Scientific Cat#11586861
L-Lysine-2HCl, 13C6 for SILAC Thermo Fisher Scientific Cat#11854191
L-Arginine-HCl, 13C6, 15N4 for SILAC Thermo Fisher Scientific Cat#11546871
Dialyzed FBS for SILAC Thermo Fisher Scientific Cat#11506871
Critical commercial assays
CellTiter 96 AQueous Non-Radioactive Cell
Proliferation Assay (MTS)
Promega Cat#G5421
Lipofectamine 2000 Invitrogen Cat#11668019
Annexin V-FITC Apoptosis Detection Reagent Abcam Cat#ab14082
GenEluteTM Mammalian Total RNA Miniprep Kit Sigma-Aldrich Cat#RTN350
SuperScriptTM VILO cDNA Synthesis Kit Invitrogen Cat#11754250
PierceTM BCA Protein Assay Kit Pierce Biotechnology Cat#23227
Dual-Luciferase Reporter Assay Promega Cat#E1980
Deposited data
RNASeq dataset GEO database GSE162648
R-code for analysis Github https://github.com/MartinFStrand/TNKSiRes
Proteomics dataset ProteomeXchange PXD022908
Experimental models: Cell lines
COLO 320DM American Type Culture Collection (ATCC) Cat#ATCC CCL220; RRID: CVCL_0219
UO-31 NCI-60 Human Tumor Cell Lines Screen/
National Cancer Institute (NCI-DTP)
Cat#UO-31; RRID:CVCL_1911
OVCAR-4 NCI-60 Human Tumor Cell Lines Screen/
National Cancer Institute (NCI-DTP)
Cat#OVCAR-4; RRID:CVCL_1627
ABC-1 Japanese Collection of Research
Bioresources Cell Bank (JCRB)
Cat#JCRB0815; RRID:CVCL_1066
RKO American Type Culture Collection (ATCC) Cat#ATCC CRL2577; RRID:CVCL_0504
Oligonucleotides
MYC (esiRNA) Sigma Aldrich Cat#EHU021051
CTNNB1 (esiRNA) Sigma Aldrich Cat#EHU139421
YAP1 (esiRNA) Sigma Aldrich Cat#EHU113021
EGFP (esiRNA) Sigma Aldrich Cat#EHUEGFP
MYC (TaqMan probe) Applied Biosystems Catt#Hs00153408_m1
CCND1 (TaqMan probe) Applied Biosystems Cat#Hs00765553_m1
AXIN2 (TaqMan probe) Applied Biosystems Cat#Hs00610344_m1
CYR61 (CCN1, TaqMan probe) Applied Biosystems Cat#Hs00155479_m1
CTGF (CCN2, TaqMan probe) Applied Biosystems Cat#Hs01026927_g1
AMOTL2 (TaqMan probe) Applied Biosystems Cat#Hs01048101_m1
GAPDH (TaqMan probe) Applied Biosystems Cat#Hs02758991_g1
Software and algorithms
Sigma Plot 12.5 Systat Software Inc. https://systatsoftware.com/products/sigmaplot/
ControlFreak Contchart software https://contchart.com/outliers.aspx
XLfit SOAPaligner/SOAP2 IDBS https://www.idbs.com/excelcurvefitting/
Software for short oligonucleotide alignment https://github.com/ShujiaHuang/SOAPaligner
(Continued on next page)
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REAGENT or RESOURCE SOURCE IDENTIFIER
NOISeq – R package for exploratory analysis and
differential expression for RNA-seq data
(Tarazona et al., 2011, 2015) https://www.bioconductor.org/packages/
release/bioc/html/NOISeq.html
Pheatmap – R package for heatmap generation Raivo Kolde https://CRAN.R-project.org/package=pheatmap
Ingenuity Pathway Analysis (IPA version 01-10) Qiagen https://digitalinsights.qiagen.com/products-
overview/discovery-insights-portfolio/
analysis-and-visualization/qiagen-ipa/
GenVisR (R package for mutation waterfall plots) Bioconductor http://bioconductor.org/packages/
release/bioc/html/GenVisR.html
MaxQuant (MaxQuant version 1.3.2.8) Max-Planck-Institute of Biochemistry https://www.maxquant.org/
Other
IncuCyte Essen BioScience Cat# FLR30140






Further information and requests for resources and reagents should be directed to and will be fulfilled by
the Lead Contact Jo Waaler (jo.waaler@rr-research.no).Materials availability
Materials generated in this study can be made available upon request to the Lead Contact.Data and code availability
Datasets and codes generated during this study are available at repositories indicated in the key resources
table. Raw and processed mRNA-sequencing data have been deposited in NCBI’s Gene Expression
Omnibus (Edgar et al., 2002) and are accessible through GEO Series accession number GSE162648
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE162648). The mass spectrometry proteomics
data have been deposited to the ProteomeXchange Consortium via the PRIDE (Perez-Riverol et al.,
2019) partner repository with the dataset identifier PXD022908. The R-code used for analysis and visualiza-
tion is available at https://github.com/MartinFStrand/TNKSiRes. Original and source data for the mutation
analysis, for the human cancer cell lines COLO320DM, OVCAR-4, U031, ABC-1 and RKO, as indicated in
Table S2, is available from Cancer Cell Line Encyclopedia (CCLE; COLO320_LARGE_INTESTINE, AB-
C1_LUNG, UO31_KIDNEY, OVCAR4_OVARY, RKO_LARGE_INTESTINE), Catalogue of Somatic Mutations
in Cancer (COSMIC; COLO-320-HSR [COSS910569], ABC-1 [COSS906791], OVCAR-4 [COSS905990], UO-
31 [COSS905981] and RKO [COSS909698]) and canSAR (Coker et al., 2019).EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines and cell culture
The human cancer cell lines COLO 320DM (colorectal adenocarcinoma, ATCCCCL220) and RKO (colon
carcinoma, ATCC CRL2577) were obtained from the American Type Culture Collection (ATCC). ABC-1
cells (lung adenocarcinoma, JCRB0815) were obtained from the Japanese Collection of Research Bio-
resources Cell Bank (JCRB). UO-31 (renal cell carcinoma) and OVCAR-4 cells (ovarian adenocarcinoma),
from the NCI-60 Human Tumor Cell Lines Screen, were provided by the National Cancer Institute (NCI).
ABC-1 and RKO were cultured in Eagle’s Minimum Essential Medium (EMEM, 30-2003, ATCC), while
COLO 320DM, OVCAR-4 and UO-31 cells were cultured in RPMI-1640 medium (R8758, Sigma-Aldrich).
Both media contained 10% Fetal Bovine Serum (FBS, 10270-106, Gibco) and 1% Penicillin-Streptomycin
(P4333, Sigma-Aldrich). Cells were cultured at 37 oC in humidified cell incubators with 5% CO2. The cell cul-
tures were kept below 20 passages (10 weeks) and routinely monitored (upon thawing and monthly) for
Mycoplasma infections with MycoAlert Mycoplasma detection kit (Lonza). All cell lines were authenticated





Human tumor cell line anti-proliferative screens
Compound screening and data analysis carried out by Genentech was performed similar to a previous
description (Haverty et al., 2016). Briefly, a collection of cancer cell lines obtained from a variety of academic
and commercial sources, such as ATCC and Leibniz Institute DSMZ-German Collection of Microorganisms
and Cell Cultures, was used. Cell line identity was routinely verified by high-throughput single nucleotide
polymorphism genotyping using multiplexed assays (Yu et al., 2015). All cell lines were cultured using stan-
dard tissue culture techniques and maintained in RPMI-1640 (31800, GIBCO), 2 mM glutamine (Kyowa
Hakko Bio), 10% FBS (F4135, Sigma) for suspension cell lines, and 5% FBS for adherent cell lines, in a hu-
midified incubator maintained at 37C and 5% CO2. Cells were plated in 384-well plates (353962, Corning)
at optimal seeding density to achieve 75% confluency at 96 hours monitored using Incucyte for live cell im-
aging (4647, Essen Bioscience). Optimal seeding for suspension and mix suspension/adherent cell lines
was determined by 75% maximal signal at 96 hours using CellTiter-Glo Luminescent Cell Viability Assay
(G7573, Promega). The day after, cell culture medium was changed to medium containing nine drug con-
centrations (using three to four replicates) or vehicle control (dimethylsulfoxide, DMSO, D2650, Sigma). Af-
ter 72 hours, 25 mL CellTiter-Glo reagent was added to the wells and luminescence readout wasmeasured
using a 2104 EnVision Multilabel Plate Reader (2105-0010, PerkinElmer). Data were processed using R (R
Core Team, 2012) and a Genentech-developed analysis package (singleAgentPlots, Dr. Richard Bourgon).
Absolute GI25 and GI50 values were calculated relative to the corresponding vehicle control.
G007-LK was screened against the NCI-60 tumor cell line panel using their standard protocol: Briefly, all cell
lines were grown in RPMI 1640 medium containing 5% FBS and 2 mM L-glutamine at 37 C and 5% CO2.
5,000-40,000 cells/well were seeded in 96-well plates depending on the cell’s doubling speeds. The day
after, cell culture medium was changed to medium containing five drug concentrations plus control. After
an additional 48 hours, adherent cells were fixed in situ by the addition of 50 ml of cold 50 % (w/v) TCA (final
concentration, 10 %) and incubated for 60 minutes at 4 C. The supernatant was discarded, and the plates
were washed five times with water and air dried. Sulforhodamine B (SRB) solution (100 ml) at 0.4 % (w/v) in 1
% acetic acid was added to each well, and the plates were incubated for 10 minutes at room temperature.
After staining, cells were rinsed five times with 1 % acetic acid and the plates were air dried. Bound SRB was
subsequently solubilized with 10 mM trizma base, and the absorbance was read on an automated plate
reader at a wavelength of 515 nm. For suspension cells, themethodology was the same except that the cells
were allowed to settle to the bottom of the well before gently adding 50 ml of 80 % TCA (final concentration
16 %). Using seven absorbance measurements (time zero [Tz], control growth [C], and test growth in the
presence of five drug concentrations [Ti]), the percentage growth inhibition (GI25 and GI50 values) was
calculated for each drug concentration using the formula: (1- [Ti-Tz]/[C-Tz]) x 100.Treatment with small-molecule inhibitors
All small-molecule inhibitors were dissolved in DMSO (D8418, Sigma-Aldrich) and kept as 10mM stocks at 4
oC. General protocol for treatment: Cells were seeded one day before treatment to reach 20 or 80%
confluence for a 72 hour or a 24 hour treatment, respectively. The medium was changed to medium con-
taining vehicle (0.01% DMSO), 1 mM or various doses of the tankyrase inhibitor G007-LK (Mercachem), PI3K
inhibitor BKM120 (CT-BKM120, Chemietek) or AKT inhibitor API-2 (2151, Tocris Bioscience).siRNA transfection
Cells were seeded in 6-well plates to reach 50-60% confluence the day after, when the cells were trans-
fected (Lipofectamine 2000, 11668019, Invitrogen) with esiRNA againstMYC (50 nM, EHU021051),CTNNB1
(50 nM, EHU139421) or YAP1 (25 nM, EHU113021), using esiRNA against EGFP (50 or 25 nM, EHUEGFP) as
control (all Sigma-Aldrich). The next day, the cells were trypsinized (T392, Sigma-Aldrich) and seeded in 96-
well plates for proliferation assays, or in 6-well plates for 48 additional hours for preparing protein extracts,
cell cycle analyses and apoptosis assays.Proliferation assays
5,000 (COLO 320DM), 2,500 (UO-31, OVCAR-4, ABC-1) or 1,000 (RKO) cells/well were seeded in 96-well
plates in at least 6 replicates for each treatment tested, also for seeding of esiRNA transfected cells. For
samples for treatment with small-molecule inhibitors, the cell culture medium was changed the day after




Articleor in an IncuCyte (FLR30140, Essen BioScience) for real-time monitoring of cell confluency. At experiment
endpoint (80-100% confluency after 5-8 days of cell growth), the cells were incubated for 1 hour at 37Cwith
CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay (MTS, G5421, Promega) according to the
supplier’s recommendations. Abs492 was measured (Wallac 1420 Victor2 Microplate Reader, Perkin Elmer)
and compared the initial Abs492 values (t0) using the following formula to determine single well values rela-
tive to the vehicle or EGFP esiRNA controls: (sample A492 - mean A492 t0)/(mean A492 [for 0.01% DMSO con-
trols] - mean A492 t0) 3100.
Colony assays
500 cells/well were seeded in 6-well plates. The day after, cell culture mediumwith 10% FBS was changed to
contain 1 mM G007-LK or vehicle (0.01% DMSO) and the plates were incubated at 37 C for 7-11 days
without replacing the medium. Colonies were stained and fixed (0.2%methylene blue [M9140] in methanol
[82762], both Sigma-Aldrich), washed with PBS, and enumerated using a colony counter (Scienceware). For
UO-31 cells, colony confluence was measured at experiment end using IncuCyte.
Cell cycle and apoptosis assays
After treatment with vehicle, G007-LK or esiRNA, both cells in suspension and trypsinized adherent cells
were collected to form a single cell suspension. Cell cycle assay: The cells were vortexed vigorously while
drop-wisely adding ice cold 70% ethanol followed by incubation at -20 oC for at least 12 hours. The cells
were then pelleted by centrifugation, washed in PBS and re-suspended in PBS containing propidium iodide
(20 mg/ml, P4170, Sigma-Aldrich], RNaseA (200 mg/ml, R5503, Sigma-Aldrich) and Triton X-100 (0.1%,
T8787, Sigma-Aldrich) for 15 minutes at 37 oC before cell cycle analysis. Apoptosis Assay: The cells were
pelleted by centrifugation and incubated for 10 minutes at 37 oC in Annexin V-FITC Apoptosis Detection
Reagent (ab14082, Abcam). PI positive and Annexin V-FITC positive cells were quantified by flow cytometry
using an Attune Acoustic Focusing Cytometer (Applied Biosystems).
RNA isolation and real-time qRT-PCR
Total mRNA was isolated from treated cells using GenEluteTM Mammalian Total RNA Miniprep Kit
(RTN350, Sigma-Aldrich) and quantified using a Nanodrop 2000c spectrophotometer (Thermo Scientific).
cDNA was synthesized with SuperScriptTM VILO cDNA Synthesis Kit (11754250, Invitrogen) and real-time
qRT-PCR (TaqManGene Expression system, Applied Biosystems) was performed using Viia7 Real-Time
PCR System (Applied Biosystems). The following probes (all from Applied Biosystems) were used: MYC
(Hs00153408_m1), CCND1 (Hs00765553_m1), AXIN2 (Hs00610344_m1), CYR61 (CCN1, Hs00155479_m1),
CTGF (CCN2, Hs01026927_g1), AMOTL2 (Hs01048101_m1) and GAPDH (Hs02758991_g1).
Western blot analysis
Cells treated with small-molecule inhibitors or esiRNA were washed with PBS and lysed in NP40 buffer
(FNN0021, Invitrogen) containing protease inhibitors (cOmplete Protease Inhibitor Cocktail,
4693116001, Roche). Pelleted nuclei were separated from the cytoplasmic-cell membrane supernatant
fractions. RIPA lysis buffer (89901, Thermo Fisher Scientific), containing phosphatase (4906845001) and pro-
tease inhibitors (4693116001, both Sigma-Aldrich) was added to the nuclei followed by sonication (Bio-
ruptorPlus, Diagenode). Protein concentrations were measured using PierceTM BCA Protein Assay Kit
(23227, Pierce Biotechnology). The protein extracts were loaded to gels (NuPAGE Novex 3-8% Tris-Ace-
tate Gel or 4-12% Bis-Tris Gel, Invitrogen), separated and transferred onto PVDF membranes (Immobilon-
PSQ PVDF Membrane, Millipore). The following primary antibodies were used to probe the membranes:
MYC (5605, Cell Signaling Technology), CCND1 (ab16663, Abcam), Tankyrase-1/2 (TNKS1/2, H-350, sc-
8337, Santa Cruz Biotechnology), AXIN1 (2087, Cell Signaling Technology), AXIN2 (2151, Cell Signaling
Technology), non-phospho (active) b-catenin (8814, Cell Signaling Technology), phospho b-catenin
(Ser33/37/Thr41)(9561, Cell Signaling Technology), b-catenin (610153, BD Biosciences), GSK3b (12456,
Cell Signaling Technology), phospho-GSK3b (Ser9)(9323, Cell Signaling Technology), AMOT (sc-166924,
Santa Cruz Biotechnology), AMOTL1 (PA5-42267, Thermo Fisher Scientific), AMOTL2 (PA5-78770, Thermo
Fisher Scientific), YAP (sc-101199, Santa Cruz Biotechnology), TAZ (HPA007415, Sigma-Aldrich), AKT (9272,
Cell Signaling Technology), phospho-AKT (Ser473)(4060, Cell Signaling Technology), phospho-AKT
(Thr308)(9275, Cell Signaling Technology), PTEN (9552, Cell Signaling Technology), AMPKa (2793, Cell
Signaling Technology) and phospho-AMPKa (Thr172)(2535, Cell Signaling Technology). Actin (A2066,





The following plasmids were used for transient co-transfections: SuperTOP-luciferase (WNT/b-catenin
signaling pathway reporter with 7xTCF binding sites: SuperTOPflash, gift from V. Korinek), FOPflash (nega-
tive control reporter with mutated TCF binding sites: SuperFOPflash-luciferase, gift from V. Korinek),
8xGTIIC-luciferase (Hippo and YAP signaling pathway reporter: 34615, Addgene, provided by S. Piccolo)
and Renilla luciferase (E2241, pRL-TK, Promega). FuGENE HD (Promega) was used for all co-transfec-
tions. For co-transfections using SuperTOPflash or FOPflash and Renilla luciferase: On day one, cells
were seeded in 48-well plates to reach 50-60% confluency on day two for co-transfections (0.23 mg lucif-
erase reporter and 0.02 mg Renilla luciferase) followed by 24 hours cultivation. For 8xGTIIC-luciferase
and Renilla luciferase co-transfections: Cells were seeded in 10-cm dishes on day one to reach 50-60% con-
fluency on day two for co-transfections (16.5 mg 8xGTIIC-luciferase and 3 mg Renilla luciferase). On day
three, the cells were trypsinized. 40,000 and 10,000 cells were seeded in 96-well plates for 24 and 72 hours
G007-LK treatments starting on day four, respectively. For generation of stable cell lines: Lentivirus packed
with 7TFP (7xTcf-FFluc//SV40-PuroR, #24308, Addgene, provided by R. Nusse), pMD2.G (VSV-G envelope
expressing plasmid, #12259, Addgene, provided by D. Trono) and psPAX2 (lentiviral packaging plasmid,
#12260, Addgene, provided by D. Trono) were used for creating lentiviral particles. All cell lines were trans-
duced and thereafter treated with 0.5-5 mg/ml Puromycin (P9620, Sigma-Aldrich) for selection. Next, the
cells lines were transduced using lentiviral particles expressing Renilla luciferase (LVP370, Amsbio) fol-
lowed by selection using 300-1,000 mg/ml Geneticin (11558616, Fisher Scientific). 40,000 and 10,000 cells
were seeded in 96-well plates for 24 and 72 hours G007-LK treatments starting the day after, respectively.
At experiment end, the cells were lysed and the luciferase activities were measured using Dual-Luciferase
Reporter Assay (E1980, Promega) and GloMax-Multi Detection System (E7031, Promega). XLfit (Idbs) was
used to calculate the 50% inhibitory concentration (IC50) using the Langmuir Binding Isotherm formula.
Structured illumination and confocal microscopy
Similar to our previous protocol (Waaler et al., 2020b), cells grown on coverslips pre-coated with poly-L-
lysine (sc-286689, Santa Cruz Biotechnology) were fixed in 4% paraformaldehyde (P6148, Sigma-Aldrich)
for 15 minutes at room temperature and permeabilized with 0.1% Triton-X100/PBS (T8787, Sigma-Aldrich,
15 minutes at room temperature). Incubation with primary antibodies (24 hours at 4 C) was followed by
incubations with secondary antibodies (1 hour at room temperature), both diluted in PBS with 4% bovine
serum albumin. Nuclear counterstaining was performed with DAPI (D9542, Sigma-Aldrich, 1 mg/mL, 5 mi-
nutes at room temperature) and coverslips were mounted in ProLong Diamond Antifade Mountant
(Thermo Fisher Scientific). The following primary antibodies were used: b-catenin (610153, 1:500, BD Bio-
sciences), Tankyrase-1/2 (H-350, sc-8337, 1:50, Santa Cruz Biotechnology), YAP (sc-101199, 1:200, Santa
Cruz Biotechnology), AMOTL2 (sc-398261, 1:50, Santa Cruz Biotechnology) and AMOTL2 (PA5-78770,
1:50, Thermo Fisher Scientific). Secondary antibodies used (both from Thermo Fisher Scientific, 1:500):
Anti-rabbit IgG Alexa488 (A-21206) and anti-Mouse IgG Alexa594 (A-11005). Structured illumination micro-
scopy (SIM) images were acquired on a Zeiss Elyra PS1 microscope system using standard filters sets and
laser lines with a Plan-APOCHROMAT 633 1.4 NA oil objective. SIM imaging was performed using 5 grid
rotations with the 0.51 mm grid for 20 Z planes with 0.184 nm spacing between planes. SIM images were
reconstructed with the following ‘‘Method’’ parameters in the ZEN black software (MicroImaging, Carl
Zeiss): Processing: Manual, Noise Filter: -5, SR Frequency Weighting: 1, Baseline Cut, Sectioning: 100/
83/83, Output: SR-SIM, PSF: Theoretical. The SIM images are displayed as maximum intensity projections
rendered from all Z planes. Confocal microscopy was performed on a Zeiss Meta 700 laser scanning
confocal microscope using standard filters sets and laser lines with a 633 oil immersion objective, images
were acquired as Z-stacks using the Zen software package (Zeiss) with 0.56 mm spacing between stacks. The
confocal images were analyzed using the Fiji software tool (Schindelin et al., 2012). Confocal images were
displayed as Z-stacks in the nucleous region.
RNA sequencing and alignment
mRNA from all cell lines were isolated then treated with DNase I (AMPD1-1KT, Sigma-Aldrich) before 4 mg
mRNA was sent to BGI Tech Solutions Company (Hong Kong) for RNA sequencing according to their stan-
dard protocol. Briefly, total RNA samples were enriched using oligo(dT) magnetic beads followed by frag-
mentation (about 200 bp). Then double-stranded cDNA was synthetized and purified, before end repara-
tion, ligation of sequencing adaptors and enrichment by PCR amplification. Quality control and
quantification was performed using Agilent 2100 Bioanalyzer and ABI StepOnePlus Real-Time PCR System




Articlereference gene set (hg19) using SOAPaligner/SOAP2 with no more than 2 mismatches allowed in the align-
ment. Gene expression level was calculated using RPKMs (reads per kb transcript per million mapped
reads).
Bioinformatics
NOISeq analysis (Tarazona et al., 2011, 2015) was used by the BGI Tech Solutions Company to identify
differentially expressed genes (DEGs) between treatment (1 mM G007-LK) and control (0.01% DMSO)
groups (both n =2). Genes with a differential expression (DE) probability > 0.8 were defined by default
as DEGs. The DE probability is calculated in NOISeq by comparing the log2 ratio of the two conditions
(M) and the value of difference between conditions (D) against the noice distribution, and a higher prob-
ability value corresponds to a higher significance (inverse of a normal P value)(Tarazona et al., 2011). As
several applications use P values as a default, the DE probability was transformed using the following for-
mula: 1-Probability. The NOISeq DE probability calculation performs well with regards to false discovery
rate (FDR) compared to other methods, and thus the inverse of the DE-probability (1-Probability) may
be used as the equivalent of a corrected P value. Volcano plots and heatmaps (using pheatmap, https://
CRAN.R-project.org/package=pheatmap) were generated in R (version 3.6.1). For each cell line, a list of
DE genes, including log2 fold change and transformed probability values (1-Probability), was analyzed
using Ingenuity Pathway Analysis (IPA) version 01-10 (Qiagen). For each cell line, log2 fold change and trans-
formed probability values from the DEGs analysis were uploaded into IPA and analyzed for upstream reg-
ulators using the core analysis function. The core analysis was performed with the Ingenuity Knowledge
Base (genes only) reference set and direct relationships, with no filters set for node types, data sources,
confidence, species, tissues & cell lines or mutations.
Mutation analysis
Mutation datasets for the cell lines were downloaded from the CCLE, COSMIC and CANSAR databases
and screened for a set of 299 driver mutations previously identified (Bailey et al., 2018) and plotted as a
waterfall plot using the GenVisR package (Skidmore et al., 2016) in R.
Proteomics
All cell lines were treated in duplicates with 1 mM G007-LK or 0.01% DMSO for 24 hours. In parallel, all cell
lines were cultured in heavy medium for SILAC labeling (11586861, RPMI 1640 Medium for SILAC;
11854191, L-Lysine-2HCl, 13C6 for SILAC; 11546871, L-Arginine-HCl, 13C6, 15N4 for SILAC; 11506871, Dia-
lyzed FBS for SILAC). After cultivation, pelleted cells were dissolved in 0.1% ProteaseMax Surfactant (V2071,
Promega) in 50 mM NH4HCO3 (A6141, Sigma-Aldrich). Samples were heated at 95
C for 15 minutes and
then sonicated for 15 minutes. After 3 freeze and thaw cycles, the samples were vigorously mixed and
passed a syringe (0.9 x 2.5 mm) to dissolve DNA, and heating and sonication was repeated as described
above. Then, the samples were centrifuged at 14,000 g before measuring the protein concentration of
the supernatant by DirectDetect (DDHW00010-W, Millipore). For each cell line, 100 mg protein was trans-
ferred to new vials and mixed with 100 mg of protein from corresponding SILAC labeled cells. Each sample
was mixed with 40 ml 0.2% ProteaseMax Surfactant in 50 mM NH4HCO3, followed by further dilution with
147 ml 50 mM NH4HCO3. Proteins were next reduced with 5 mM 1,4-dithiothreitol (D9779-10G, Sigma-Al-
drich) at 56 C for 20 minutes, and subsequent digestion with 4 mg trypsin (V5111, Promega) overnight at 37
C. Peptides were desalted on a C18 StageTip made with three layers of C18 Empore Extraction disks
(98060402140, 3M), and eluted with 80% acetonitrile (ACN, 34851, Sigma-Aldrich)/0.1% formic acid (FA,
533002, Merck). The eluate was dried on a SpeedVac (5305000100, Eppendorf) until the volume reached
approximately 3 ml. The sample was next reconstituted to a total volume of 14 ml in 0.1% FA. nLC-MS/
MS analysis was performed on a nEASY-LC system coupled to a Q-Exactive Plus mass spectrometer (IQ-
LAAEGAAPFALGMBDK, both Thermo Fisher Scientific). A 25 cm EasySpray column (C18, 2 mm beads,
100 Å, 75 mm inner diameter, S802, Thermo Electron) was used to separate peptides, using a 120 minutes
gradient up to a concentration of 30%. Solvent A (0.1% FA) and solvent B (100% ACN with 0.1% FA) was
used with a flow rate of 0.3 ml/minutes. The mass spectrometer was operated in a data-dependent
mode with top 10 MS/MS scans, and the survey of full-scan MS spectra was from 300–1750 m/z. MS scan
parameters were as follows: lock mass: off, resolution: 70,000, AGC target: 3e6, and maximum IT: 50 ms.
The MS/MS scans were performed at: resolution: 17,500, AGC target: 2e5, maximum IT: 100 ms, isolation
window: 3.0 m/z, NCE: 25, underfill ratio: 10.0%, intensity threshold: 2.0e5, and dynamic exclusion: 30.0 s.
Protein identification and label-free quantitation was performed in MaxQuant (version 1.3.2.8) using the




Articlethe human UniProt database (October 2014 version) supplemented with contaminants. The applied param-
eters were: enzyme: trypsin/P; variable modifications: oxidation (M), acetyl (protein N-term), Phospho
(STY), hydroxyproline and deamidation (NQ); labels: Arg10, Lys6, max. peptide PEP: 0.1; min. peptide
length: 7; min. unique peptides: 1; advanced: re-quantity, keep low-scoring versions of identified peptides,
match between runs (0.7 min time window), label-free quantitation, and second peptideMS2 identification.
Otherwise, the default parameters of MaxQuant were used. Normalized L/H abundance ratios were calcu-
lated in MaxQuant, and the ratios of treated versus control for each cell line were analyzed for differential
protein abundance using NOISeq analysis in R. Volcano plots of differential protein abundance were
generated in R.QUANTIFICATION AND STATISTICAL ANALYSIS
Sigma Plot 12.5 (Systat Software Inc.) was used for all statistical analyses with the exception of bioinfor-
matics analyses using NOISeq, IPA and R. Single outlier detections were identified by Dixon’s and/or
Grubb’s tests (threshold, P < 0.05) using ControlFreak (Contchart software). Detailed descriptions of statis-
tical tests used, description of the number of events (n) as well as depictions of mean and standard devi-
ations can be found in the figure legends and figures. The minimum significance level was defined as
P < 0.05. The two-tailed Student’s t-test was used to test for significant differences (*** [P < 0.001], **
[P < 0.01] and * [P < 0.05]) between two samples with normally distributed parameters (Shapiro-Wilk
test, P > 0.05). Mann-Whitney tests were used to test for significant differences (z [P < 0.01] and y [P <
0.05]) between two samples with parameters that were not normally distributed. One way ANOVA tests
(Holm-Sidak method versus control) were used to test for significant differences (*** [P < 0.001], ** [P <
0.01] and * [P < 0.05]) between multiple samples with normally distributed parameters (Shapiro-Wilk
test, P > 0.05). One way ANOVA on ranks tests (Dunn’s method versus control) were used to test for signif-
icant differences (z [P < 0.01] and y [P < 0.05]) between multiple samples with parameters that were not
normally distributed. NOISeq analysis was performed in R. Sample sizes were determined based on exper-
iment experience, pilots experiments as well as what was reported in the literature. For the NOISeq anal-
ysis, the default probability value of > 0.8 was considered significant.26 iScience 24, 102807, July 23, 2021
